We are live on
!
Find out more
AGRX
Agile Therapeutics
AGRX
AGRX
Delisted
AGRX was delisted on the 25th of March, 2024.
26 hedge funds and large institutions have $28M invested in Agile Therapeutics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
19,200% more call options, than puts
Call options by funds: $386K | Put options by funds: $2K
412% more capital invested
Capital invested by funds: $5.47M → $28M (+$22.5M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
7
Reduced
4
Closed
4
Calls
$386K
Puts
$2K
Net Calls
+$384K
Net Calls Change
+$297K
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
+$8.93M |
| 2 |
Renaissance Technologies
New York
|
+$206K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$138K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$110K |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$106K |
Top Sellers
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$57.2K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19.1K |
| 3 |
Morgan Stanley
New York
|
-$12.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.36K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$6K |
